Atlas Venture Associates Opportunity I, L.P. — SEC Form 4 filings

SEC reporting owner CIK 1780065. 10 Form 4 filings on record with FilingPulse; latest filed 2026-02-09.

Transaction summary — filings shown

Covers all 10 filings on record, filed 2024-01-12 to 2026-02-09. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Dyne Therapeutics, Inc. (DYN)10% owner326 legs · 1,355,161 sh · $32,365,030
Kymera Therapeutics, Inc. (KYMR)10% owner112 legs · 353,357 sh · $14,912,376
Disc Medicine, Inc. (IRON)10% owner25 legs · 200,000 sh · $13,347,500
Xilio Therapeutics, Inc. (XLO)10% owner26 legs · 5,235 sh · $4,240
Generation Bio Co. (GBIO)10% owner13
Vigil Neuroscience, Inc. (VIGL)10% owner12

Form 4 filings — Atlas Venture Associates Opportunity I, L.P.

FiledFormIssuerReported transactionsSource
2026-02-094Generation Bio Co. (GBIO)
jointly with Atlas Venture Fund X, L.P., ATLAS VENTURE ASSOCIATES X, L.P., Atlas Venture Associates X, LLC, Atlas Venture Opportunity Fund I, L.P., Atlas Venture Associates Opportunity I, LLC
Code (U): 711,193 · Code (U): 116,693 · Code (U): 60EDGAR
2025-08-074Vigil Neuroscience, Inc. (VIGL)
jointly with Atlas Venture Fund XII, L.P., Atlas Venture Associates XII, L.P., Atlas Venture Associates XII, LLC, Atlas Venture Opportunity Fund I, L.P., Atlas Venture Associates Opportunity I, LLC
Disposition to issuer (D): 4,808,896 · Disposition to issuer (D): 1,027,978EDGAR
2024-03-134Kymera Therapeutics, Inc. (KYMR)
jointly with Atlas Venture Fund X, L.P., ATLAS VENTURE ASSOCIATES X, L.P., Atlas Venture Associates X, LLC, Atlas Venture Opportunity Fund I, L.P., Atlas Venture Associates Opportunity I, LLC
Sale (S): 37,180 @ $42.77 · Sale (S): 5,122 @ $43.42 · Sale (S): 7,837 @ $42.77 · Sale (S): 1,045 @ $43.42 · Sale (S): 126,066 @ $41.94 · Sale (S): 8,581 @ $42.52 · +6 moreEDGAR
2024-03-054Dyne Therapeutics, Inc. (DYN)
jointly with Atlas Venture Opportunity Fund I, L.P., Atlas Venture Associates Opportunity I, LLC, Atlas Venture Opportunity Fund II, L.P., Atlas Venture Associates Opportunity II, LP, Atlas Venture Associates Opportunity II, LLC
Sale (S): 29,435 @ $30.05 · Sale (S): 17,099 @ $30.05EDGAR
2024-02-284Dyne Therapeutics, Inc. (DYN)
jointly with Atlas Venture Fund XI, L.P., Atlas Venture Associates XI, L.P., Atlas Venture Associates XI, LLC, Atlas Venture Opportunity Fund I, L.P., Atlas Venture Associates Opportunity I, LLC, Atlas Venture Opportunity Fund II, L.P., Atlas Venture Associates Opportunity II, LP, Atlas Venture Associates Opportunity II, LLC
Sale (S): 136,312 @ $23.59 · Sale (S): 64,783 @ $23.98 · Sale (S): 20,205 @ $23.59 · Sale (S): 9,603 @ $23.98 · Sale (S): 11,736 @ $23.59 · Sale (S): 5,580 @ $23.98 · +12 moreEDGAR
2024-02-234Dyne Therapeutics, Inc. (DYN)
jointly with Atlas Venture Fund XI, L.P., Atlas Venture Associates XI, L.P., Atlas Venture Associates XI, LLC, Atlas Venture Opportunity Fund I, L.P., Atlas Venture Associates Opportunity I, LLC, Atlas Venture Opportunity Fund II, L.P., Atlas Venture Associates Opportunity II, LP, Atlas Venture Associates Opportunity II, LLC
Sale (S): 149,337 @ $22.44 · Sale (S): 35,164 @ $23.14 · Sale (S): 119,360 @ $22.66 · Sale (S): 159,542 @ $22.70 · Sale (S): 23,648 @ $22.70 · Sale (S): 13,738 @ $22.70EDGAR
2024-02-094Xilio Therapeutics, Inc. (XLO)
jointly with Atlas Venture Fund XI, L.P., Atlas Venture Associates XI, L.P., Atlas Venture Associates XI, LLC, Atlas Venture Opportunity Fund I, L.P., Atlas Venture Associates Opportunity I, LLC
Sale (S): 733 @ $0.64 · Sale (S): 267 @ $0.64EDGAR
2024-01-254Disc Medicine, Inc. (IRON)
jointly with Atlas Venture Fund X, L.P., ATLAS VENTURE ASSOCIATES X, L.P., Atlas Venture Associates X, LLC, Atlas Venture Opportunity Fund I, L.P., Atlas Venture Associates Opportunity I, LLC, Atlas Venture Opportunity Fund II, L.P., Atlas Venture Associates Opportunity II, LP, Atlas Venture Associates Opportunity II, LLC
Sale (S): 47,500 @ $67.65 · Sale (S): 82,500 @ $67.65 · Sale (S): 20,000 @ $67.65EDGAR
2024-01-164Xilio Therapeutics, Inc. (XLO)
jointly with Atlas Venture Fund XI, L.P., Atlas Venture Associates XI, L.P., Atlas Venture Associates XI, LLC, Atlas Venture Opportunity Fund I, L.P., Atlas Venture Associates Opportunity I, LLC
Sale (S): 1,566 @ $0.87 · Sale (S): 569 @ $0.87 · Sale (S): 1,540 @ $0.83 · Sale (S): 560 @ $0.83EDGAR
2024-01-124Disc Medicine, Inc. (IRON)
jointly with Atlas Venture Fund X, L.P., ATLAS VENTURE ASSOCIATES X, L.P., Atlas Venture Associates X, LLC, Atlas Venture Opportunity Fund I, L.P., Atlas Venture Associates Opportunity I, LLC
Sale (S): 30,000 @ $64 · Sale (S): 20,000 @ $64EDGAR

FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1780065 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →